Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Hangzhou Tigermed Consulting - A (300347.SZ)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (Rmb)	Price Target (Rmb)	Rating
2021-08-20	135.87	205.64	Buy
2021-12-15	128.60	186.70	Buy
2022-04-11	98.23	154.78	Buy
2022-08-26	104.91	147.28	Buy
2022-09-20	91.77	139.00	Buy
2022-10-26	88.85	129.00	Buy
2023-03-29	102.66	137.00	Buy
2023-09-28	68.32	73.00	Neutral
2023-10-28	61.07	66.80	Neutral
2024-03-15	52.10	54.30	Neutral
2024-04-25	53.01	54.00	Neutral
2024-06-12	57.60	76.60	Buy
2024-08-28	48.68	70.40	Buy
2024-11-05	67.99	79.20	Buy

Disclosures

Market capitalisation is calculated by multiplying the current share price by the sum of A and H shares.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.